MedTrace Logo

Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients

NCT00290394 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2006-02-13

No results posted yet for this study

Summary

The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure-reducing effects.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

rosiglitazone(drug), blood pressure lowering effect

Sponsors & Collaborators

  • Baskent University

    lead OTHER

Principal Investigators

  • Neslihan B Tutuncu, MD · Medical Doctor, Endocrynology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
49 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Completion
2004-08-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290394 on ClinicalTrials.gov